SCHEMBL6165129

SCHEMBL6165129

CCCN(C)c1cc2c(cc1C)NC(=O)CC(c1cccc(C#N)c1)=N2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167282 0.89
SCHEMBL6165450 0.81 GRM2 (0.45)
SCHEMBL6166720 0.81
SCHEMBL6164610 0.80 GRM2 (0.52)
SCHEMBL6166940 0.79 CYP3A4 (0.42)
SCHEMBL6162891 0.79 GRM2 (0.42)
SCHEMBL6167278 0.78 CYP3A4 (0.42)
SCHEMBL7143588 0.78
SCHEMBL6167963 0.78 CYP3A4 (0.55)
SCHEMBL6167295 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed